James T. Barrett

Jim Barrett, a partner in Goodwin’s Private Equity group, is a business and securities lawyer who represents life sciences and other technology companies as well as venture capital and private equity funds. He regularly counsels boards of directors and general partners on corporate governance matters and guides their businesses through all stages of development. Accordingly, Jim concentrates on investment transactions, mergers and acquisitions, securities law and general corporate representation.

Jim serves as Co-Chair of Goodwin’s Pro Bono Committee.

Jim has significant corporate counsel experience:

• Accuratus Lab Services
• Albert Einstein College of Medicine of Yeshiva University
• Ampersand Capital Partners
• Arranta Bio
• Avista Pharma Solutions
• Bakotic Pathology Associates
• BioInnovation Capital
• Boston Heart Diagnostics Corporation
• Brammer Bio, LLC
• ChanTest Corporation
• Confluent Medical Technologies, Inc.
• Corpus Medical, Inc.
• CRILifetree
• Dynex Technologies, Inc.
• Elite One Source Nutritional Services, Inc.
• Forum Pharmaceuticals Inc.
• Gelesis, Inc.
• Genoptix, Inc.
• GnuBIO Inc.
• iCarbonX Group Limited
• Lab Central Inc.
• MainStPBC
• Magellan Biosciences, Inc.
• Mission BioCapital
• Mitokinin, Inc.
• Modified Polymer Components, Inc.
• Montefiore Medical Center
• MPM Capital
• N2 Biomedical LLC
• Nexelis
• PureTech Health plc
• Rand Worldwide, Inc.
• Solasia Pharma K.K.
• StageBio
• Stemline Therapeutics, Inc.
• Tal Medical, Inc.
• TriPharm Services, Inc.
• Two Lanterns Venture Partners
• ViraCor-IBT Laboratories, Inc.

Jim’s work has included representing and/or advising:

• Ampersand Capital Partners in its 10th private equity fund (Ampersand 2020 LP) which raised $690 million from limited partners, with plans to target promising companies in the health care sector.
• Nexelis Group Inc., through a newly acquired European subsidiary Nexelis Europe, in the acquisition of 100% of the share capital and voting rights of the Belgium company ImmunXperts.  The completion of the transaction was backed by Ampersand Capital Partners, Nexelis being a portfolio company of the latter.
• Vibalogics Holdings LLC, a portfolio company of Ampersand Capital Partners, in the sale of preferred equity to multiple investors. 
• Ampersand Capital Partners and Brammer Bio in its sale to Thermo Fisher Scientific (NYSE: TMO) for $1.7 billion. Brammer Bio is a leading viral vector contract development and manufacturing organization enabling biopharma customers to deliver breakthrough medicines to patients using gene therapies and gene-modified cell therapies.
• Karuna Therapeutics, Inc. in its $100 million initial public offering and $250 follow-on offering. Karuna is an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. Karuna is a portfolio company of PureTech Health plc.
• Ampersand Capital Partners in its PIPE investment of $27 million in Series A Preferred Stock of Interpace Biosciences, Inc. (Nasdaq: IDXG) and subsequent exchange of its Series A Preferred Stock for an equivalent amount of newly created Series B Preferred Stock and an additional $1 million of Series B Preferred Stock. Interpace is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.
• TriPharm Services, Inc. in its sale to Alcami Corporation, an affiliate of Madison Dearborn Partners. TriPharm is a contract development and manufacturing organization offering parenteral manufacturing options for pharma and biotechnology clients. 
• Arranta Bio, a contract development and manufacturing organization (CDMO) focused on providing development and commercialization services for therapeutic companies targeting the human microbiome, in its initial financing, strategic partnership with Thermo Fisher Scientific, and acquisition of Captozyme. Captozyme is a leading CDMO helping microbiome pioneers develop therapies for the gut using novel enzymes and live biotherapeutics.
• Ampersand Capital Partners in its acquisition of a majority stake in N2 Biomedical, a leading provider of coating and surface treatment services for a wide range of medical and dental applications.
• Lab Central Inc. in its formation, financing and establishment of 501(c)(3) status.
• Ampersand Capital Partners in its acquisition of Vibalogics GmbH from the PHW Group. Vibalogics is a CDMO with facilities in Cuxhaven, Germany, providing process development and GMP manufacturing services. Founded in 2002, the company is recognized as a leading service provider within the live biologics development and manufacturing industry.
• resTORbio, Inc. in its $97.8 million initial public offering. resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. resTORbio is a portfolio company of PureTech Health plc.
• Gelesis, a medical product developer focused on treating weight loss and obesity, in growth equity financings and licensing, collaboration, commercialization and manufacturing matters. Gelesis is a portfolio company of PureTech Health plc.
• BioInnovation Capital in its investments in several early-stage life sciences companies, including Avexegen, Epiodyne, Graphwear, Mediar, Mitokinin, Photoswitch Biosciences, Photoswitch Therapeutics, PanTher Therapeutics, QurAlis, Shape Therapeutics, Tidal Therapeutics, Totient, Vaxess Technologies and Vedere Bio.
• Confluent Medical Technologies, Inc. as general corporate counsel. Confluent is a global leader in medical device contract manufacturing.
• iCarbonX Group Limited in the sale of all of the issued and outstanding equity of PatientsLikeMe LLC to United HealthCare Services, Inc., an affiliate of United Health Group.
• The formation of iCarbonX in a business combination of PatientsLikeMe, HealthTell Inc. and iCarbonX Offshore Holdings Limited, a subsidiary of iCarbonX (Shenzhen) Company Limited. iCarbonX and its subsidiaries provide a global personalized health platform direct to consumers to enable them to make informed decisions about lifestyle, health and care through their lives using proprietary systems biology, digital profiling technologies and closed loop learning.
• Confluent Medical Technologies, Inc. in its acquisition of Tube Hollows International. Confluent is a global leader in medical device contract manufacturing.
• Ampersand Capital Partners in its acquisition through its portfolio company, HSRL Holdings LLC, of HSRL Archives, LLC.
• Ampersand Capital Partners in its acquisition through its portfolio company, HSRL Holdings LLC, of Vet Path Services, Inc. and VPS Archives, LLC.
• Ampersand Capital Partners in growth investments in Nexcelom Bioscience and NEOMED Laboratories (now Nexelis).
• Corpus Medical Holding, LLC in its business combination with Confluent Medical Technologies in a stock-for-stock merger.
• Ampersand Capital Partners in its acquisition of Pacific Biomarkers. PacBio is a biomarker testing services provider, supporting pharmaceutical, biotech and in-vitro diagnostic (IVD) manufacturing companies through preclinical and Phase I-IV studies of drug and IVD development.
• Ampersand Capital Partners in its acquisition of MedPharm Limited and its wholly owned subsidiary MP Pharma Services, Inc. MedPharm Limited is the world's leading contract provider of topical and transdermal product design and development services.
• Ampersand Capital Partners in its 9th private equity fund (Ampersand 2018 LP) which raised $450 million from limited partners.
• Avista Pharma Solutions, a contract provider of drug substance, drug product and analytical services, in its sale to Cambrex Corporation.
• Confluent Medical Technologies, Inc. in its acquisitions of Interface Catheter Solutions, a contract manufacturer of balloon catheter systems, and Corpus Medical, a contract developer and manufacturer of interventional medical devices. Confluent is a global leader in medical device contract manufacturing.
• Bakotic pathology Associates, LLC in the sale of a majority interest in Bako Integrated Physician Solutions in a recapitalization backed by Consonance Capital Partners. Bako is a premier national provider of specialty laboratory testing services which offers a comprehensive testing menu, including complete anatomic pathology services, proprietary molecular genetic testing, and peripheral neuropathy immuno-histochemical testing.
• The sale of Innovative Food Processors, Inc. to Balchem Corporation.
• The sale of Dynex Technologies, Inc. to Telegraph Hill Partners.
• Ampersand Capital Partners and its portfolio company Magellan Biosciences, Inc. (Magellan) in the sale of Magellan for a purchase price of $66 million to Meridian Bioscience, Inc., a fully integrated life science company that develops, manufactures, markets and distributes a broad range of diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies.
• Ampersand Capital Partners and 1315 Capital in their acquisition of Genoptix, Inc., a provider of comprehensive testing solutions in hematology and solid tumor molecular profiling, from Novartis Pharmaceuticals Corporation.
• The sale of Agilux Laboratories, Inc. to Charles River Laboratories International, Inc.
• Ampersand Capital Partners in its acquisition of a majority stake in Corpus Medical, a provider of consulting and manufacturing services for development and commercialization of interventional medical devices.
• Florida Biologix in its merger with Brammer Biopharmaceuticals LLC, forming Brammer Bio, LLC, a cell and gene therapy biologics contract development and manufacturing organization.
• Avista Pharma in its acquisition of the GMP contract manufacturing, development and animal health services business of Scynexis, Inc. (NASDAQ: SCYX).
• Nitinol Devices and Components, Inc. (NDC) in its acquisition of Interface Catheter Solutions (Interface). NDC is the largest contract manufacturer of nitinol-based medical devices and Interface is a pioneer in medical balloon technology and the leading contract manufacturer of balloon catheter systems. Following the acquisition, NDC and Interface created Confluent Medical Technologies, a leading contract manufacturer of specialized medical devices.
• Ampersand Capital Partners in its acquisition of Protein Technologies, a maker of peptide synthesizers  and reagents.*
• Accuratus Lab Services in its acquisition of the chemistry, manufacturing and control testing services business of Array BioPharma.*
• ChanTest Corporation, a leading private equity backed provider of specialized laboratory testing services  for drug development, in its acquisition by Charles River Laboratories.*
• Charles River Ventures in its Series A financing of a technology startup company.*
• Ampersand Capital Partners in its minority investment in CutisPharma, an industry leader in prescription compounding pharmaceuticals.*
• NutraMed in its acquisition of Nutritional Laboratories International, Inc.*
• ViraCor-IBT Laboratories, Inc., a premier specialty diagnostics laboratory, as general counsel, in several bolt‑on acquisitions, and in its acquisition by Eurofins Scientific for a purchase price of approximately $255 million.*
• GnuBIO Inc., a developer of fully integrated droplet-based DNA sequencing technology, as general counsel and in its acquisition by Bio-Rad Laboratories, Inc. in a merger transaction including milestone-based contingent payments.*
• Ampersand Capital Partners in the sale of CoreLab Partners, Inc. and take-private of Bioclinica, Inc., both global clinical trial solutions businesses.*
• Stemline Therapeutics, Inc. in its initial public offering.*
• Modified Polymer Components, Inc. in its acquisition of Biomedical Structures, LLC.*
• Ampersand Capital Partners in the acquisition of clinical toxicology laboratories.*
• Sanofi-Genzyme BioVentures in its Series A financing of 4s3 Bioscience, Inc.*
• K-TEK Corp. in its sale to ABB, the global power and automation technology group.*
• Ampersand Capital Partners in its investments in Blue Sky Biotech, a contract research organization; Modified Polymer Components, a manufacturer of polymer components for medical device OEMs; and Accuratus Lab Services, an antimicrobial testing services business.*
• Magellan Biosciences in the sale of its microbiology testing products division, TREK Diagnostic Systems, to Thermo Fischer Scientific.*
• Ampersand Capital Partners in the take-private of Rand Worldwide, Inc., and Rand Worldwide, Inc. in its subsequent alternative public offering (APO) through a reverse merger.*
• IBT Laboratories in its merger with ViraCor Laboratories, forming ViraCor-IBT Laboratories, a leading specialty diagnostics testing lab.*
• A syndicate of investors, including MPM Capital and Oxford Bioscience Partners, in their investment in Radius Health.*
• Ampersand Capital Partners and SV Life Sciences in the acquisition of a controlling interest in CRI Worldwide, a leading provider of clinical research services to the pharmaceutical industry.*
• MPM Capital and New Enterprise Associates in their investment in Rhythm, a biotechnology company developing peptide therapeutics for metabolic diseases.*
• Ampersand Capital Partners in the leveraged buyout of K TEK Corp., a leading global manufacturer of state-of-the-art level instrumentation for liquid and bulk solids detection.*
• Protient, Inc. in its sale to a major multi-national corporation.*
• MPM Capital in the acquisition by Novartis AG of a majority stake in Idenix for $255 million, plus contingent payments, as well as in Idenix’s IPO and follow-on offering.*
• PharmAthene in its sale to Healthcare Acquisition Corp., in which Mr. Barrett represented Bear Stearns Health Innoventures, HealthCare Ventures and MPM Capital as the major stockholders of PharmAthene. Mr. Barrett had previously represented these investors in a $50 million financing of PharmAthene.*
• The $350 million sale of TriPath Imaging (TPTH) to a leading medical technology company.*
• The Series A Financing for Syndax Pharmaceuticals Inc., a company developing novel oncology products through mechanistically driven combination regimens, in which Mr. Barrett represented MPM Capital and Pappas Ventures.*
• The Series A Financing for Claros Diagnostics, a company developing a proprietary microfluidics device to improve diagnostics in prostate cancer and other urology disorders, in which Mr. Barrett represented Oxford Bioscience Partners.*
• The Series A financing for Cequent Pharmaceuticals, a company developing new clinically compatible therapies based on RNA interference, in which Mr. Barrett represented Ampersand Capital.*
• The Series C Financing for Elixir Pharmaceuticals, a company developing therapeutics to treat age‑related diseases, in which Mr. Barrett represented MPM Capital.*
• MPM Capital in its investment in Xanodyne Pharmaceuticals, a pain and women’s health company, and Xanodyne’s simultaneous acquisition of assets from aaiPharma for $209 million.*
• The acquisition of Trek Diagnostic Systems and simultaneous Series A Financing of Magellan Biosciences, a clinical diagnostics company whose lead investors are Ampersand Capital and Abingworth Management.*
• MPM Capital in the sale of its interest in Idea AG to Celtic Pharmaceutical Holdings L.P.*
• Oxford Bioscience Partners in the $20 million investment in and reorganization of Alantos Pharmaceuticals AG as a Delaware corporation.*
• Cerimon Pharmaceuticals in its $70 million Series A Preferred Stock financing.*
• Ampersand Capital Partners and SV Life Sciences in their investment in M2 Worldwide Corporation (Medifacts), a Maryland-based provider of cardiac monitoring and other clinical trial services.*
• Open Ratings, Inc., a venture-backed on-line supply chain management company, in its acquisition by Dun & Bradstreet, Inc.*
• Ampersand Capital Partners in its buyout of Princeton Radiology Pharmaceutical Research, a Princeton, New Jersey based provider of radiological services for use in clinical and other environments.*
• Transport Pharmaceuticals in its conversion to a corporation and $27 million initial round of financing.*
• Magellan Biosciences, a clinical diagnostics company, in its acquisition of TekCel, Inc.*

*Denotes experience prior to joining Goodwin.

Prior to joining Goodwin in 2015, Jim was a partner at Locke Lord in Boston, where he served as co-chair of its private equity/venture capital group.

Jim has been recognized by The Best Lawyers in America Best Lawyers for his work in Corporate Law 2022-2023.